Purpose: Enzyme replacement therapy (ERT) has recently became available for Pompe disease. Data on the effects of ERT on physiological variables related to exercise tolerance have never been published. Methods: Pulmonary gas exchange, cardiac output (by impedance cardiography), and vastus lateralis muscle O 2 extraction (by near-infrared spectroscopy) were determined during cycle ergometer exercise in a 50-yr-old patient before and after 1, 12, and 24 months of ERT. Results: At the same constant-workload submaximal exercise, RPE, R, pulmonary ventilation, and HR were lower during ERT versus before, suggesting an increased exercise tolerance. Peak oxygen uptake (V̇O 2peak) increased by ∼35% from before (0.64 L•min -1 or 11.4 mL•kg -1•min -1)...
INTRODUCTION: The clinical course of late-onset Pompe disease is heterogeneous, and new clinical out...
Background: Pompe disease is an inheritable metabolic disorder for which enzyme replacement therapy ...
textabstractObjectives: Pompe disease is a progressive metabolic myopathy for which enzyme replaceme...
Purpose: Enzyme replacement therapy (ERT) has recently became available for Pompe disease. Data on t...
Background: Enzyme replacement therapy (ERT) with alglucosidase alfa improves the prospect of patien...
Background: Late onset Pompe disease (LOPD) is a lysosomal neuromuscular disorder which can progress...
textabstractBackground: Pompe disease is a rare metabolic myopathy for which disease-specific enzyme...
Contains fulltext : 111047.pdf (publisher's version ) (Open Access)ABSTRACT: BACKG...
textabstractBackground: Pompe disease is a proximal myopathy. We investigated whether exercise train...
Pompe disease is a progressive myopathy resulting from deficiency in lysosomal enzyme acid α-glucosi...
In patients with late-onset Pompe disease (LOPD), the efficacy of the enzyme replacement therapy (ER...
International audienceObjective: Pompe disease (glycogenosis type II) is caused by lysosomal alpha-g...
Objective: To examine respiratory muscle function among late-onset Pompe disease (LOPD) patients in ...
Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage di...
Background: Pompe disease, first described in 1932, is a glycogen storage disorder as well as a lyso...
INTRODUCTION: The clinical course of late-onset Pompe disease is heterogeneous, and new clinical out...
Background: Pompe disease is an inheritable metabolic disorder for which enzyme replacement therapy ...
textabstractObjectives: Pompe disease is a progressive metabolic myopathy for which enzyme replaceme...
Purpose: Enzyme replacement therapy (ERT) has recently became available for Pompe disease. Data on t...
Background: Enzyme replacement therapy (ERT) with alglucosidase alfa improves the prospect of patien...
Background: Late onset Pompe disease (LOPD) is a lysosomal neuromuscular disorder which can progress...
textabstractBackground: Pompe disease is a rare metabolic myopathy for which disease-specific enzyme...
Contains fulltext : 111047.pdf (publisher's version ) (Open Access)ABSTRACT: BACKG...
textabstractBackground: Pompe disease is a proximal myopathy. We investigated whether exercise train...
Pompe disease is a progressive myopathy resulting from deficiency in lysosomal enzyme acid α-glucosi...
In patients with late-onset Pompe disease (LOPD), the efficacy of the enzyme replacement therapy (ER...
International audienceObjective: Pompe disease (glycogenosis type II) is caused by lysosomal alpha-g...
Objective: To examine respiratory muscle function among late-onset Pompe disease (LOPD) patients in ...
Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage di...
Background: Pompe disease, first described in 1932, is a glycogen storage disorder as well as a lyso...
INTRODUCTION: The clinical course of late-onset Pompe disease is heterogeneous, and new clinical out...
Background: Pompe disease is an inheritable metabolic disorder for which enzyme replacement therapy ...
textabstractObjectives: Pompe disease is a progressive metabolic myopathy for which enzyme replaceme...